机构名称：
¥ 2.0
1 ebitda fy 2022年针对与获得Corat，Corat，Candoro道德规范（前C 3），Cernelle和Nutravis的收购有关的非重新持续成本进行了调整，与进一步的收购努力，Fitvia和Spectrum，Cilian（Corat of Corat of Corat of Corat of Corat of Corniriens of Corniriens of Corent of Cornian for Corent of Cortirient）有关咨询成本，咨询成本C 3和执行委员会的遣散费（通过集体持有调整）| EBITDA组还包括-750万欧元的EBITDA（集团持有）。EBITDA FY 2023 adjusted for non-recurring costs of €29.9m in connection with the acquisition of Arkopharma and Montavit, consulting costs in connection with further acquisition efforts, restructuring of fitvia and Candoro ethics NM, impairment of Corat, deconsolidation effects of fitvia, bellavia, mibe UK, Corat and Gynial, income from the realisation of a negative差异（montavit）。
FY 2023
主要关键词
相关文件推荐
